EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage

Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh und 3 weitere

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfae008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Veronika Keresteš und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove 500 05, Czech Republic. Hauptthemen laut MEDLINE: Topoisomerase II Inhibitors, Anthracyclines, Quinoxalines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Czech Science Foundation, Charles University, European Regional Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anthracyclines, such as doxorubicin (adriamycin), daunorubicin, or epirubicin, rank among the most effective agents in classical anticancer chemotherapy. However, cardiotoxicity remains the main limitation of their clinical use. Topoisomerase IIβ has recently been identified as a plausible target of anthracyclines in cardiomyocytes. We examined the putative topoisomerase IIβ selective agent XK469 as a potential cardioprotective and designed several new analogs. In our experiments, XK469 inhibited both topoisomerase isoforms (α and β) and did not induce topoisomerase II covalent complexes in isolated cardiomyocytes and HL-60, but induced proteasomal degradation of topoisomerase II in these cell types. The cardioprotective potential of XK469 was studied on rat neonatal cardiomyocytes, where dexrazoxane (ICRF-187), the only clinically approved cardioprotective, was effective. Initially, XK469 prevented daunorubicin-induced toxicity and p53 phosphorylation in cardiomyocytes. However, it only partially prevented the phosphorylation of H2AX and did not affect DNA damage measured by Comet Assay. It also did not compromise the daunorubicin antiproliferative effect in HL-60 leukemic cells. When administered to rabbits to evaluate its cardioprotective potential in vivo, XK469 failed to prevent the daunorubicin-induced cardiac toxicity in either acute or chronic settings. In the following in vitro analysis, we found that prolonged and continuous exposure of rat neonatal cardiomyocytes to XK469 led to significant toxicity. In conclusion, this study provides important evidence on the effects of XK469 and its combination with daunorubicin in clinically relevant doses in cardiomyocytes. Despite its promising characteristics, long-term treatments and in vivo experiments have not confirmed its cardioprotective potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Topoisomerase II InhibitorsAnthracyclinesQuinoxalinesRatsAnimalsRabbitsCardiotoxicityDaunorubicinDoxorubicinAntibiotics, AntineoplasticDNA Topoisomerases, Type IIDNA Damage

Stichwörter der Autor:innen

XK469anthracyclinescardiotoxicitydexrazoxanetopoisomerase II

Substanzen

Topoisomerase II InhibitorsAnthracyclinesXK 469DaunorubicinDoxorubicinAntibiotics, AntineoplasticDNA Topoisomerases, Type IIQuinoxalines

Autor:innen und Institutionen

  • Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove 500 05, Czech Republic.
  • Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove 500 03, Czech Republic.
  • Department of Organic and Bioorganic chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove 500 05, Czech Republic.
  • National Center of Hematology, Mustansiriyah University, Baghdad, Baghdad Governorate 79R2+RXM, Iraq.
  • Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove 500 05, Czech Republic.
  • Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Förderung

  • Czech Science Foundation
  • Charles University
  • European Regional Development

Zitieren

APA

Keresteš, V., Kubeš, J., Applová, L., Kollárová, P., Lenčová-Popelová, O., Melnikova, I., Karabanovich, G., Khazeem, M. M., Bavlovič-Piskáčková, H., Štěrbová-Kovaříková, P., Austin, C. A., Roh, J., Štěrba, M., Šimůnek, T., & Jirkovská, A. (2024). Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae008

Vancouver

Keresteš V, Kubeš J, Applová L, Kollárová P, Lenčová-Popelová O, Melnikova I, et al. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae008

BibTeX
@article{Kereste2024,
  author = {Keresteš, Veronika and Kubeš, Jan and Applová, Lenka and Kollárová, Petra and Lenčová-Popelová, Olga and Melnikova, Iuliia and Karabanovich, Galina and Khazeem, Mushtaq M and Bavlovič-Piskáčková, Hana and Štěrbová-Kovaříková, Petra and Austin, Caroline A and Roh, Jaroslav and Štěrba, Martin and Šimůnek, Tomáš and Jirkovská, Anna},
  title = {Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfae008}
}
Kostenlos starten →